Why Fundoscopy Before Starting Semaglutide
Fundoscopy should be performed before initiating semaglutide to identify pre-existing diabetic retinopathy, as patients with established retinopathy—particularly those with poor glycemic control—face a significantly increased risk of retinopathy complications when starting this medication.
The Core Risk: Rapid Glycemic Improvement in Vulnerable Eyes
The FDA label for semaglutide explicitly warns that diabetic retinopathy complications occurred more frequently with semaglutide (3.0%) versus placebo (1.8%) in cardiovascular outcome trials 1. The absolute risk increase was dramatically higher among patients with pre-existing diabetic retinopathy at baseline (8.2% with semaglutide vs 5.2% placebo) compared to those without known retinopathy (0.7% vs 0.4%) 1.
This phenomenon is not unique to semaglutide—it reflects a well-established pattern where rapid improvement in glucose control causes temporary worsening of diabetic retinopathy 1. The mechanism involves rapid HbA1c reduction triggering microvascular changes in already-compromised retinal tissue.
Who Is at Highest Risk
Analysis of the SUSTAIN 6 trial data reveals the highest-risk profile 2:
- Pre-existing diabetic retinopathy at baseline
- Poor glycemic control (high baseline HbA1c)
- Concurrent insulin therapy
- Rapid HbA1c reduction (>1.0% decrease in first 16 weeks)
The mediation analysis demonstrated that the magnitude and rapidity of HbA1c reduction during the first 16 weeks was the primary driver of retinopathy complications in vulnerable patients 2. Meta-analysis confirms that decreases in HbA1c correlate with increases in diabetic retinopathy complications (log rr = -0.67*(ΔA1c), p=0.076), with the effect most pronounced when HbA1c drops exceed 1.0% 3.
What the Guidelines Mandate
Current ADA guidelines explicitly state: "Retinopathy status should be assessed when glucose-lowering therapies are intensified, such as those using GLP-1 RAs, since rapid reductions in A1C can be associated with initial worsening of retinopathy" 4. This represents a direct recommendation to evaluate retinal status before intensifying therapy with agents like semaglutide.
The 2025 ADA Standards further specify that all patients with type 2 diabetes should have a comprehensive dilated eye examination at diagnosis 4, which naturally precedes any treatment initiation.
The Clinical Algorithm
Before prescribing semaglutide:
Obtain recent fundoscopic examination (within past year for patients without retinopathy; more recent if any retinopathy present)
Document retinopathy status:
- No retinopathy → Proceed with standard monitoring
- Any level of retinopathy present → High-risk patient requiring enhanced surveillance
For patients with pre-existing retinopathy:
- Ensure ophthalmology follow-up is established
- Consider slower titration if baseline HbA1c is very elevated (>9-10%)
- Plan for ophthalmologic re-evaluation within 3-6 months of starting therapy
- Monitor for symptoms: new floaters, vision changes, flashing lights
Document baseline HbA1c to anticipate magnitude of reduction
Important Caveats
The FDA label specifically states: "Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy" 1. This is a regulatory warning that cannot be ignored.
However, context matters: The number needed to harm for retinopathy worsening with semaglutide is 77, while the number needed to treat for major adverse cardiovascular events is 43 3. The cardiovascular benefits substantially outweigh retinopathy risks in most patients, but this calculation requires knowing the baseline retinal status.
Recent large-scale observational data from 810,390 semaglutide users found no increased risk of proliferative diabetic retinopathy or treatment-requiring diabetic macular edema compared to other diabetes medications 5. This suggests the risk may be concentrated in the specific high-risk subgroup identified above rather than being a broad class effect.
The Bottom Line
Fundoscopy before semaglutide initiation serves two critical purposes: (1) identifying the high-risk patients who need enhanced monitoring, and (2) establishing a baseline for comparison if retinopathy symptoms develop during treatment. This is not optional—it's mandated by current guidelines for intensification of glucose-lowering therapy 4 and explicitly recommended in the FDA drug label 1.